Page 157 - Multidisipliner Covid 19

Enfeksiyon Hastal›klar› Uzman› Gözünden COV‹D-19 ve Kalp

coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;
22(5):911-915. doi:10.1002/ejhf.1828
15. Zhou R. Does SARS-CoV-2 cause viral myocarditis in COVID-19 pati-
ents? Eur Heart J. 2020;41(22):2123. doi:10.1093/eurheartj/ehaa392
16. Brojakowska A, Narula J, Shimony R, Bander J. Clinical Implications
of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC
Review Topic of the Week. J Am Coll Cardiol. 2020;75(24):3085-3095.
doi:10.1016/j.jacc.2020.04.028
17. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19)
and Cardiovascular Disease: A Viewpoint on the Potential Influence
of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor
Blockers on Onset and Severity of Severe Acute Respiratory Syndrome
Coronavirus 2 Infec. J Am Heart Assoc. 2020;9(7):e016219. doi:10.1161/
doi:10.1161/JAHA.120.016219
18. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA,
Solomon SD. Renin-angiotensin-aldosterone system inhibitors in pati-
ents with covid-19. N Engl J Med. 2020;382(17):1653-1659. doi:10.1056/
NEJMsr2005760
19. Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COV-
ID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020;22(5):20-
23. doi:10.1007/s11886-020-01291-4
20. Lee KCH, Sewa DW, Phua GC. Potential role of statins in COVID-19.
Int J Infect Dis. 2020;96:615-617. doi:10.1016/j.ijid.2020.05.115
21. Castiglione V, Chiriacò M, Emdin M, Taddei S, Vergaro G. Statin thera-
py in COVID-19 infection. Eur Hear journal Cardiovasc Pharmacother.
Published online 2020. doi:10.1093/ehjcvp/pvaa042
22. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac Com-
plications Attributed to Chloroquine and Hydroxychloroquine: A
Systematic Review of the Literature. Drug Saf. 2018;41(10):919-931.
doi:10.1007/s40264-018-0689-4

156